Odonate Therapeutics, Inc. (ODT)

$1.12

-0.05 (-4.27%)
Rating:
Recommendation:
Buy
Symbol ODT
Price $1.12
Beta 0.453
Volume Avg. 0.96M
Market Cap 43.109M
Shares () -
52 Week Range 0.85-28.41
1y Target Est -
DCF Unlevered ODT DCF ->
DCF Levered ODT LDCF ->
ROE -102.72% Strong Sell
ROA -96.50% Strong Sell
Operating Margin -
Debt / Equity 48.20% Neutral
P/E -
P/B 0.60 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ODT news


Mr. Kevin Tang
Healthcare
Biotechnology
Nasdaq Global Select

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.